4th – 6th September 2017Darwin Convention Centre | Northern Territory
AUSTRALIAN AND NEW ZEALAND
SOCIETY OF NEPHROLOGY (ANZSN)
53rd ANNUAL SCIENTIFIC MEETING
2 ANZSN | ANNUAL SCIENTIFIC MEETING
SPONSORS
GOLD SPONSORS
SILVER SPONSOR
BRONZE SPONSOR
PAD/PEN SPONSOR
BARISTA SPONSOR
NAME BADGE SPONSOR
DIETITIAN DAY SPONSORS
UPDATE COURSE SPONSOR
MEETING APP SPONSOR
3DARWIN, NT | 4 – 6 SEPTEMBER 2017
OFFICE BEARERS
PRESIDENTProfessor Jonathan Craig
PRESIDENT ELECTA/ Prof Nigel Toussaint
HONORARY EXECUTIVE OFFICERA/Prof Germaine Wong
TREASURERA/Professor Girish Talaulikar
COUNCILDr Katherine Barraclough
Dr Ross Francis
Dr Jaquelyn Hughes
Dr Joshua Kausman
Dr Murray Leikis
A/Prof David Mudge
LOCAL ORGANISING COMMITTEE CO-CHAIRSDr Paul Lawton
Dr Sandawana William Majoni
SCIENTIFIC PROGRAM AND EDUCATION COMMITTEEA/Professor Angela Webster (Chair)
Professor Francesco Ierino
A/Professor Sharon Ricardo
A/Professor Wai Lim
A/Professor Dr Gopi Rangan
Dr John Irvine
Dr Muh Geot Wong
Dr Robert MacGinley
A/Prof Greg Tesch
Dr Andrew Mallett
Dr Peter Trnka
Dr Martin Gallagher (2018 LOC)
ANZSNExecutive Officer
Ms Anna Golebiowski
Administrative Officer
Ms Jourdan Pinnell
PROFESSIONAL CONFERENCE ORGANISERConference Design Pty Ltd
4 ANZSN | ANNUAL SCIENTIFIC MEETING
On behalf of the Australian and New Zealand Society of Nephrology’s President, Jonathan Craig, the Scientific Program and Education Committee and the Local Organising Committee, we welcome you to the 53rd Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, to being held from 4th to 6th September 2017 in Darwin.
The Scientific Program and Education Committee, chaired by Associate Professor Angela Webster, has planned a first-rate program, around the theme “ Equity and Diversity”.
Expert international and national speakers will bring you the very latest advances and contemporary summaries in nephrological science and clinical care. As is now customary, this will be complemented by the pre-meeting ANZSN Update Course and the ANZSIN meeting afterwards.
Darwin is an exciting destination with much more to offer than just the headlines. We’re confident you’ll find your visit to Darwin memorable and enjoyable, both scientifically and socially.
Yours sincerely,
Dr. Paul Lawton & Dr. William MajoniCo-Chairs, Local Organising Committee
WELCOME
5DARWIN, NT | 4 – 6 SEPTEMBER 2017
SPEAKERS
PLENARY SPEAKERS
A/Professor Camille KottonClinical Director, Transplant Infectious Disease and Immunocompromised Host Program, Massachusetts General Hospital
Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts
Professor Laura DemberProfessor of Medicine and Epidemiology at the University of Pennsylvania Perelman School of Medicine
Faculty Member, Renal-Electrolyte and Hypertension Division
Senior Scholar, Center for Clinical Epidemiology and Biostatistics
Professor Charmaine E LokProfessor of Medicine at the University of Toronto
Medical Director of both the multidisciplinary chronic kidney disease (CKD) and hemodialysis programs at the University Health Network-Toronto General Hospital
SEMINAR SPEAKERS
Dr Basu GopalDr Cara HildrethProfessor Karin Jandeleit-DahmProfessor Masaomi NangakuProfessor Carol Pollock
Professor Sharon RicardoDr Cherie StaynerProfessor Motoko YanagitaAssociate Professor Allison Tong
6 ANZSN | ANNUAL SCIENTIFIC MEETING
SOCIAL FUNCTIONS
Nephrology & Transplantation Update Course DinnerDate: Saturday 2 September 2017
Time: 6:30pm – 10:30pm
Location: Crocosaurus Cove
Dress: Smart Casual (please wear shoes suitable for walking around exhibits)
Welcome Reception & Poster ViewingDate: Monday 4 September 2017
Time: 5:30pm - 7:00pm
Location: Exhibition Area (Halls 2/3)
Night at the MoviesDate: Monday 4 September 2017
Time: 7:05pm - 9:45pm
Location: Deckchair Cinema
Dress: Smart Casual (please wear shoes suitable for walking)
ANZSN ASM Sunset Gala DinnerDate: Tuesday 5 September 2017
Time: 7:00pm until Late
Location: DCC Forecourt
Dress: Smart Casual
Entertainment: B2M Acoustic
7DARWIN, NT | 4 – 6 SEPTEMBER 2017
23
The following rooms can be divided:
Auditorium:into two equal spaces
Halls 1 – 4: into three spaces
Meeting Rooms:into two or four spaces
Waterfront Rooms:into three spaces
Operable walls
Cafe/Bar
Accessible Toilets
Baby Change
Pay Phone
Toilets
Stairs
Escalators
Lift
Conco
urse
Foyer
Foyer
Foyer
Hall 4
Hall 3
Hall 2
Hall 1
Door 2
Auditorium 2
Cafe/Bar
Auditorium 1
Auditorium 2
Auditorium 1
1
34
MeetingRooms
RegistrationDesk
OrganisersO�ce
Porte Cochere
Concourse
Load
ing
Dock
Acces
s to
unde
rgro
und
car p
ark
Roller Door
Rear car park
DarwinHarbour
Door 4
Door 5
Door 6 Door 7
CentreAdministration
LEVEL 1
GROUND LEVEL
LEVEL 2
2
2
3
1
WaterfrontRooms
DARWIN CONVENTION CENTRE FLOOR PLANS
VENUE FLOORPLAN
BREAKOUTS
PLENARY
PLENARY
REGISTRATION
EXHIBITION & CATERING
SPEAKERS PREPARATION ROOM
8 ANZSN | ANNUAL SCIENTIFIC MEETING
Nephrology and Transplantation Update Course Waterfront 2, Darwin Convention Centre
Infection diseases and the kidneys
SATURDAY 2ND SEPTEMBER 2017 – DAY 10730 Update Course Registration Concourse,
Ground Level, DCC
Theme 1: Infection disease & the kidneys Chair: Paul Lawton
0800-0830 INFECTION RELATED GLOMERULONEPHRITIS
Asanga Abeyaratne
0830-0900 DIAGNOSIS, TREATMENT AND PREVENTION OF CATHETER RELATED BLOODSTREAM INFECTIONS
Charmaine Lok
0990-0930 MALARIA, DENGUE AND THE KIDNEYS
Basu Gopal*
0930-1000 CMV INFECTION: WHAT IS HOT? WHAT IS NEW?
Camille Kotton
1000-1030 Morning Tea Foyer, Level 2
Theme 2: Renal Replacement Therapy Chair: Muh Geot Wong
1030-1100 CAN WE PREDICT THE UNPREDICTABLE AFTER VASCULAR ACCESS CREATION?
Kevan Polkinghorne
1100-1300 UPDATE IN PERITONEAL DIALYSIS
Matthew Jose
1130-1200 ENVIRONMENTAL IMPACT OF RENAL CARE
Katherine Barraclough
1200-1300 Lunch Foyer, Level 2
Theme 3: Glomerular disease Chair: Katherine Barraclough
PRE ASM COURSES
* APSN SPEAKER
9DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
E ASM
CO
UR
SES
1300-1330 UPDATE IN TREATMENTS FOR SYSTEMIC AMYLOIDOSIS
Laura Dember
1330-1400 UPDATE IN ANCA VASCULITIS
Robert MacGinley
1400-1430 UPDATE IN THEARPIES FOR IGA NEPHROPATHY
Muh Geot Wong
1430-1500 UPDATE IN THERAPIES FOR DIABETIC NEPHROPATHY
Carol Pollock
1500-1530 Afternoon Tea Foyer, Level 2
Theme 4: End stage kidney disease Chair: William Majoni
1530-1600 MANAGING VIRAL HEPATITIS IN CKD AND ESKD
Jane Davies
1600-1630 FGF23-AND KLOTHO HOW MUCH SHOULD YOU KNOW?
Nigel Toussaint
1630-1700 WHAT SHOULD BE ON THE PLATE? FOODS FOR ADVANCED CKD
Maria Chan
1830 till late
Nephrology and Transplantation Update Course Dinner Crocosaurus CoveCrocosaurus Cove, located in the heart of Darwin city, allows visitors a unique, up close and personal view of Australia’s iconic Saltwater Crocodiles.Bringing together some of the largest Saltwater Crocodiles in Australia & boasting the World’s largest display of Australian reptiles, Crocosaurus Cove is a must see attraction when visiting Darwin and the Top End.
10 ANZSN | ANNUAL SCIENTIFIC MEETING
Nephrology and Transplantation Update Course Waterfront 2, Darwin Convention Centre
SUNDAY 3RD SEPTEMBER 2017 – DAY 20730 Update Course Registration Waterfront 2 Foyer, Darwin
Convention Centre
Theme 5: Transplantation – recipient Chair: Angela Webster
0800-0830 IMMUNODIAGNOSTICS FOR TB, CMV, AND “NET STATE OF IMMUNOSUPPRESSION” IN TRANSPLANT RECIPIENTS
Camille Kotton
0830-0900 HOW TO INTERPRET DONOR SPECIFIC ANTIBODY (DSA)- FOR NON TRANSPLANT PHYSICIAN
Kate Wyburn
0900-0930 BACTERIAL AND FUNGAL INFECTIONS IN THE IMMUNOSUPPRESSED PATIENT -CASE STUDY DISCUSSION
Catherine Marshall
Theme 6: Transplantation – donor Chair: Angela Webster
0930-1000 RISK IN KIDNEY DONATION: HOW MUCH IS TOO MUCH?
Helen Pilmore
1000-1030 Morning Tea Foyer, Level 2
Theme 6: Transplantation – donor Chair: Frank Ierino
1030-1100 CANCER AND DONOR ASSESSMENT
Angela Webster
1100-1130 THE KIDNEY DONOR RISK INDEX (KDRI): A CASE BASED DISCUSSION
Kate Wyburn
Theme 7: Chronic kidney disease Chair: Frank Ierino
1100-1130 URIC ACID AND CKD
Sunil Badve
1130-1200 UPDATE IN ONCONEPHROLOGY
Motoko Yanagita*
1200-1300 Lunch Foyer, Level 2
* APSN SPEAKER
11DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
E ASM
CO
UR
SES
1200-1300 ATC INFORMATION SESSION | WATERFRONT 2
Vincent Lee and Natasha Rogers
Theme 7: Chronic kidney disease Chair: Muh Geot Wong
1300-1330 COGNITIVE FUNCTION AND CKD
John Death
1330-1400 SYNDROMIC CKD
Peter Trnka
Theme 8: Research Chair: Muh Geot Wong
1400-1430 EPIGENETIC AND CKD
Masaomi Nangaku*
1430-1500 DATA LINKAGE- WHERE TO START?
Sradha Kotwal
1500-1530 Afternoon Tea Foyer, Level 2
Theme 8: Research Chair: Andrew Mallett
1530-1600 CARDIO METABOLIC RISK AND CKD IN ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLE
Jaquelyne Hughes
Theme 9: Pregnancy Chair: Andrew Mallett
1600-1630 MANAGEMENT OF BP IN PREGNANCY
Vincent Lee
1630-1700 PRE-EXISTING CHRONIC KIDNEY DISEASE AND PREGNANCY
Shilpa Jesudason
1700 Course concludes
* APSN SPEAKER
12 ANZSN | ANNUAL SCIENTIFIC MEETING
Renal Dietitians Update Day Program Darwin Convention Centre Meeting Room 2
SUNDAY 3RD SEPTEMBER 20170800 Welcome to Country
0815 Update from DAA Renal IG ChairpersonKaren Salamon, APD
0830 Group activityWHAT IS GOOD EDUCATION?
0900 SHARING EXPERIENCES WORKING WITH MAORI AND PACIFIC ISLANDER POPULATIONS
Jennifer Robb
0930 INDIGENOUS HEALTH – NORTHERN TERRITORY CONTEXT AND PATIENT JOURNEY
NT Dietitians
1000 Morning Tea Foyer, Level 2
1030 Food security and access issues in AustraliaSUCCESSES OF WORKING WITH THE FOOD INDUSTRY IN REMOVING SALT FROM THE FOOD SUPPLY
Associate Professor Julie Brimblecombe
1115 BODY COMPOSITION DIFFERENCES IN ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLE
Dr Jacqui Hughes
1200 Lunch Foyer, Level 2
1300 HEALTH LITERACY – WHAT IS IT AND WHY IS IT IMPORTANT?
Associate Professor Kerry TaylorThe Health Literacy session is designed to be interactive. Participants are encouraged to bring along their educational resources for discussion amongst the group
1330 THE COGNITIVE IMPACTS ON CKD
Associate Professor Angela Webster
PRE ASM COURSES
13DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
E ASM
CO
UR
SES
1400 WHAT IS THE LATEST EVIDENCE AND RESEARCH TELLING US ABOUT WHAT PEOPLE UNDERSTAND OF NUTRITIONAL MESSAGES
Ms Kelly Lambert
1500 Afternoon Tea Foyer, Level 2
1530 Panel DiscussionThe Health Literacy session is designed to be interactive. Participants are encouraged to bring along their educational resources for discussion amongst the group
1615 Wrap up for the day
1630 Day concludes
14 ANZSN | ANNUAL SCIENTIFIC MEETING
SUNDAY 3RD SEPTEMBER 2017 (PRE-ASM)0800-1700 Council Meeting | Meeting Room 4, Ground Level, DCC
1200-1400 CPAC Meeting | Meeting Room 3, Ground Level, DCC
1430-1630 LOC Meeting for WCN 2019 | Meeting Room 1, Ground Level, DCC
1600-1800 RAC Meeting | Meeting Room 3, Ground Level, DCC
1800-2000 PKD Public Seminar | Meeting Room 2, Ground Level, DCC
1900 President’s Dinner (by invitation only) | Char Restaurant
MONDAY 4TH SEPTEMBER 2017 – ANZSN ASM 20170700 Registration Desk Open Concourse,
Ground Level, DCC
0700 Speakers Preparation Room Meeting Room 4, Ground Level, DCC
0700-0815 Nephrology Editorial Board Meeting Meeting Room 3, Ground Level, DCC
0700-0800 AKTN PISCES TSC Meeting Foyer, Level 2 Fo Meeting Room 1, Ground Level, DCC
Plenary 1 Auditorium 2
Chairs: Carmel Hawley & Jonathan Craig
0800-0815 Welcome to Country – Indigenous RepresentativeWelcome to Delegates – Dr Paul Lawton, ASM Co-Chair
0815-0900 Plenary Speaker: Laura DemberPRAGMATIC CLINICAL TRIALS: AN APPEALING ALTERNATIVE
0900-0930 TJ Neale Award
0930-1000 Jacquot Award Past RecipientsNatasha Rogers & Katherine Barraclough
PROGRAM
15DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
1000-1030 Morning Tea Exhibition Area, Hall 2-3, Ground Level, DCC
Young Investigator Award Prize Orals Auditorium 2
Chair: Carol Pollock
1030-1045 OVERALL AND SITE SPECIFIC CANCER MORTALITY IN PATIENTS ON RENAL REPLACEMENT THERAPY
Eric Au
1045-1100 JNK1 BUT NOT JNK2 PROMOTES RENAL ISCHAEMIA/REPERFUSION INJURY
Keren Grynberg
1100-1115 IDENTIFYING A CORE VASCULAR ACCESS OUTCOME FOR ALL TRIALS IN HAEMODIALYSIS: AN INTERNATIONAL SURVEY WITH PATIENTS AND HEALTH PROFESSIONALS
Andrea Viecelli
1115-1130 BLOCKADE OF KCA3.1 WITH TRAM34 ATTENUATES ESTABLISHED DIABETIC NEPHROPATHY
Chunling Huang
1130-1145 DIETARY N-3 AND N-6 POLYUNSATURATED FATTY ACID INTAKE AND RISK OF MORTALITY IN PEOPLE ON HEMODIALYSIS: THE DIET-HD MULTINATIONAL COHORT STUDY
Valeria Saglimbene
1145-1200 NLRP3 INFLAMMASOME BLOCKADE ATTENUATES DISEASE IN ANTI-MPO GLOMERULONEPHRITIS
Holly Hutton
1200-1215 IDENTIFYING IMPORTANT OUTCOMES FOR CHILDREN WITH CHRONIC KIDNEY DISEASE AND THEIR CAREGIVERS: FOCUS GROUPS WITH NOMINAL GROUP TECHNIQUE
Camilla Hanson
1215-1230 BLOCKADE OF RIPK3 ATTENUATES FOLIC ACID-INDUCED KIDENY FIBROSIS OF C57BL/6 MOUSE
Ying Shi
1230-1330 Lunch Exhibition Area, Hall 2-3, Ground Level, DCC
Amgen Australia Pty Ltd, ABN 31 051 057 438, Level 7, 123 Epping Road, North Ryde, NSW 2113. AU-0841 August 2017. NEPH6828 BBK08/17.
INNOVATION
IN EVERYTHING WE DO
RELIABILITY
THAT PERSISTS
QUALITY
FROM THE START
17DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
1330-1500 Mini Orals Session 5 minute presentation, 2 minute questions
Mini Orals Waterfront 1
General Nephrology – Epidemiology
Mini OralsWaterfront 2
Transplantation
Mini OralsWaterfront 3
Haemodialysis and Peritoneal Dialysis
Chairs: Germaine Wong & Anna Francis
Chairs: Wai Lim & Doreen Wang
Chairs: Peter Kerr & Murray Leikis
THE ROLE OF TUMOUR NECROSIS FACTOR RECEPTOR 1 (TNFR1) IN THE PROGRESSION OF KIDNEY DISEASE IN INDIGENOUS AUSTRALIANS: THE EGFR FOLLOW-UP STUDY
Federica Barzi
THE BENEFITS AND COSTS OF SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION COMPARED WITH DIALYSIS AND KIDNEY-ALONE TRANSPLANTATION IN PATIENTS WITH TYPE 1 DIABETES MELLITUS AND END-STAGE KIDNEY DISEASE
Rashmi Shingde
EXERCISE WITH BLOOD FLOW RESTRICTION DURING DIALYISIS SAFE AND TOLERABLE
Catherine A Brumby
AUTONOMOUS DECISION-MAKING IN ADULTS WITH CHRONIC KIDNEY DISEASE
Charlotte McKercher
PRE-ECLAMPSIA IN PREGNANCIES AFTER KIDNEY TRANSPLANTATION (KT): DETERMINANTS AND IMPACT ON PREGNANCY AND GRAFT OUTCOMES
Shilpanjali Jesudason
ENDOVASCULAR EVENTS, HEART FAILURE AND SURVIVAL IN DIALYSIS PATIENTS
Brendan Smyth
IMPACT OF PRIVATE HEALTH INSURANCE ON DIALYSIS OUTCOMES – A COHORT STUDY
Arunan Sriravindrarajah, Sradha Kotwal
IMPACT OF RISK-BASED, DECEASED-DONOR KIDNEY ALLOCATION ALGORITHM ON GRAFT AND PATIENT SURVIVAL
Vaishnavi Calisa
THE UPTAKE OF HAEMODIAFILTRATION IN AUSTRALIA AND NEW ZEALAND: AN ANZDATA REGISTRY STUDY
Emily See
RESEARCH OUTPUTS REPORTING INDIGENOUS HEALTH OUTCOMES IN THE AUSTRALIA AND NEW ZEALAND DIALYSIS AND TRANSPLANT REGISTRY (ANZDATA): SYSTEMATIC REVIEW
Suetonia Palmer
HUMAN LEUKOCYE ANTIGEN (HLA)-DQA AND DQB EPLET MISMATCHES AND DE NOVO DONOR-SPECIFIC ANTI-HLA-DQ ANTIBODY
Wai Lim
PREVALENCE AND PATTERNS OF COGNITIVE IMPAIRMENT IN ADULTS ON HAEMODIALYSIS: THE COGNITIVE-HD STUDY
Anita Van Zwieten
18 ANZSN | ANNUAL SCIENTIFIC MEETING
PREVALENCE AND CORRELATES OF DEPRESSION IN ADULTS WITH CHRONIC KIDNEY DISEASE
Charlotte Mckercher
AN OBSERVATIONAL STUDY OF INSULIN RESISTANCE IN PATIENTS WITH POST TRANSPLANT DIABETES MELLITUS ON DPP-4 INHIBITOR THERAPY AND OTHER AGENTS
Srivathsan Thiruvengadam
FRUIT INTAKE AND CARDIOVASCULAR AND ALL-CAUSE MORTALITY IN ADULTS ON HEMODIALYSIS: THE DIET-HD MULTINATIONAL COHORT STUDY
Valeria Saglimbene
SEX MATTERS: GENDER-RELATED DIFFERENCE IN RENAL REPLACEMENT THERAPY (RRT) INCIDENCE RATES
Stephen Mcdonald
INCIDENCE, TYPES AND PREDICTORS OF ACUTE REJECTION IN INDIGENOUS KIDNEY TRANSPLANT RECIPIENTS IN WESTERN AUSTRALIA
Prue Howson
CHANGE OF SUBJECTIVE GLOBAL ASSESSMENT (SGA) SCORE IS ASSOCIATED WITH A CHANGE IN SERUM ALBUMIN AND HAND GRIP STRENGTH
Maria Chan
ABSOLUTE RISK AND RISK FACTORS FOR STROKE MORTALITY IN PATIENTS WITH END STAGE KIDNEY DISEASE (ESKD): RETROSPECTIVE POPULATION-BASED COHORT USING DATA LINKAGE
Nicole De La Mata
WHY DON’T ALL LIVING KIDNEY DONOR CANDIDATES PROCEED TO DONATION?
Ellie Cash
IMPROVING THE SAFETY OF HAEMODIALYSIS BY OPTIMISING ANTICOAGULATION (ISHAN): A PILOT STUDY
Matthew Jose
ASSOCIATION OF DIALYSIS ATTENDANCE WITH KIDNEY TRANSPLANT OUTCOMES IN NORTHERN TERRITORY (NT) BASED KIDNEY TRANSPLANT RECIPIENTS
Namrata Khanal
A SYSTEMATIC REVIEW OF INCIDENCE AND PREVALENCE OF HIV IN INCREASED RISK GROUPS IN AUSTRALIA TO AID DECISION-MAKING IN INCREASED RISK ORGAN DONOR REFERRALS
Karen Waller
WHICH BLOOD PRESSURE MEASUREMENTS SHOULD DRIVE THERAPY IN A TRIAL OF INTENSIVE VERSUS USUAL TREATMENT OF HYPERTENSION IN HEMODIALYSIS PATIENTS?
Antonia Harford
PROGRESSION OF KIDNEY DISEASE IN A COHORT OF CHRONIC KIDNEY DISEASE (CKD) PATIENTS
Wendy Hoy
ASSOCIATION BETWEEN EPLET HLA-MISMATCHES, DE NOVO DSA PRODUCTION AND RISK OF REJECTION IN PAEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
Ankit Sharma
RAPID FLOW CYTOMETRIC IDENTIFICATION AND ANALYSIS OF STAPHYLOCOCCUS SPP. FROM PERITONEAL DIALYSATE
Aron Chakera
19DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
NEPHROLOGISTS’ PERSPECTIVES ON CANCER SCREENING IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Laura J James
LONG-TERM OUTCOME OF OVERSEAS KIDNEY TRANSPLANT RECIPIENTS – A REGISTRY ANALYSIS
Wai Lim
OBESITY IS NOT ASSOCIATED WITH INCREASED MORTALITY IN AUSTRALIA AND NEW ZEALAND PERITONEAL DIALYSIS PATIENTsSuresh Murthy
COMPARISON OF FACT AND CAUSE OF DEATH BETWEEN ANZDATA AND THE NATIONAL DEATH INDEX
Matthew Sypek
LONG-TERM GRAFT AND PATIENT OUTCOMES OF KIDNEY TRANSPLANT RECIPIENTS WITH INCIDENT CANCER – A POPULATION COHORT STUDY
Wai Lim
EARLY MESOTHELIAL CELL RESPONSES TO STAPHYLOCOCCUS EPIDERMIDIS INFECTION
Aron Chakera
ASSOCIATION OF DIALYSIS ATTENDANCE WITH WAITLISTING OF NORTHERN TERRITORY (NT) BASED END STAGE KIDNEY DISEASE (ESKD) PATIENTS
Namrata Khanal
ESTABLISHMENT OF A “RISK CALCULATOR” FOR KIDNEY TRANSPLANT RECIPIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
David Goodman
PRE-STERNAL PERITONEAL DIALYSIS CATHETERS: 14-YEAR EXPERIENCE IN A SINGLE CENTRE
LaiWan Chan
1500-1530 Afternoon Tea Exhibition Area, Hall 2-3, Ground Level, DCC
1530-1700 Seminar & KHA Awards
Seminar 1 : Basic Science Auditorium 2
Translational PKD Symposium
KHA Award Orals Waterfront 2
Chairs: Jackie Phillips & Gopala Rangan
Chair: Angela Webster
1530-1550 BASIC SCIENCE: RENAL PRIMARY CILIA AS REGULATORS OF EPITHELIAL REPAIR AND RELEVANCE TO PKD
Sharon Ricardo
DIFFICULT CONVERSATIONS: AUSTRALIAN INDIGENOUS PATIENTS’ VIEWS ON KIDNEY TRANSPLANTATION
Alan Cass
20 ANZSN | ANNUAL SCIENTIFIC MEETING
1550-1610 EPIGENETICS: TISSUE SPECIFIC TARGETING OF THERAPIES FOR PKD
Cherie Stayner
CHRONIC KIDNEY DISEASE IN AUSTRALIAN GENERAL PRACTICE: ITS PREVALENCE, AND ASSOCIATED PATIENT CHARACTERISTICS AND COMORBIDITIES
Matthew Jose
1610-1630 PRECLINICAL STUDIES: PKD, HEART DISEASE AND THE AUTONOMIC NERVOUS SYSTEM
Cara Hildreth
ADVERSE PREGNANCY OUTCOMES IN WOMEN WITH KIDNEY DISORDERS – A POPULATION STUDY OF >400,000 PREGNANCIES IN SOUTH AUSTRALIA (SA): 1990-2012
Alyssa Fitzpatrick
1630-1650 TREATMENT OUTCOMES: STANDARDISED OUTCOMES IN NEPHROLOGY
Allison Tong
EFFECTS OF FISH OIL SUPPLEMENTATION AND ASPIRIN USE ON ARTERIOVENOUS FISTULA PATENCY, NEED FOR INTERVENTIONS AND DIALYSIS SUITABILITY IN PATIENTS REQUIRING HAEMODIALYSIS – POST HOC ANALYSIS OF THE FAVOURED STUDY
Andrea Viecelli
1650-1700 PANEL THE IMPACT OF CHRONIC KIDNEY DISEASE (CKD) ON THE QUALITY OF LIFE OF CHILDREN AND ADOLESCENTS
Anna Francis
ASSOCIATION BETWEEN DURATION OF DELAYED GRAFT FUNCTION AND ALLOGRAFT OUTCOME AFTER KIDNEY TRANSPLANTATION
Wai Lim
1700-1730 ANZSN Annual General Meeting Waterfront 1
1730-1900 Welcome Reception & Poster Viewing Exhibition Area
1900 Walk to Deckchair (5 mins), follow the committee!
1905-2145 Night at the Movies Deckchair Cinema
21DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
TUESDAY 5TH SEPTEMBER 2017- ANZSN ASM 20170730 Registration Desk Open Concourse,
Ground Level, DCC
0700 Speakers Preparation Room Meeting Room 4 Ground Level, DCC
0700-0745 Australasian Kidney Trials Network Meeting Room 1-2, Breakfast Meeting (fully booked) Ground Level, DCC
Plenary 2 Auditorium 2
Chair: Nikki Isbel & Robyn Langham
0800-0900 Plenary Speaker: Camille KottonPRETRANSPLANT EVALUATION FROM AN INFECTIOUS DISEASE PERSPECTIVE: SCREENING, VACCINES, AND ENHANCING SAFETY
0900-0930 Equity and diversity in ANZSNAngela Webster
WIRELESSNETWORK NAME: ANZSN ASM
PASSWORD: anzsnasm
MONTHLY EFFICACY
1#
# Maintaining target Hb levels in CKD patients with anaemia, with monthly administration.
methoxy polyethylene glycol-epoetin beta
Please review the complete Product Information before prescribing, available at www.roche-australia.com/productinfo/mircera or phone 1800 233 950.
MINIMUM PRODUCT INFORMATION MIRCERA® (methoxy polyethylene glycol-epoetin beta) Indications: Treatment of anaemia associated with chronic kidney disease (CKD). Dosage & Administration: Administered by IV or SC injection. Use the lowest dose of MIRCERA that will gradually increase the Hb concentration. The recommended Hb target is 100 - 120 g/L. Patients not currently treated with an ESA: Not on dialysis - recommended starting dose is 1.2 µg/kg body weight monthly as a single SC injection or alternatively 0.6 µg/kg body weight, once every 2 weeks (IV or SC). On dialysis - recommended starting dose is 0.6 µg/kg body weight, once every 2 weeks. Patients currently treated with an ESA: recommended starting dose (monthly or fortnightly) is based on the previous weekly ESA dose as per below;
Previous Darbepoetin alfa dose (µg/wk) Previous Epoetin dose (IU/wk) MIRCERA dose* (µg/month)
< 4040 – 80
> 80
< 80008000 – 16000
> 16000
120200360
*fortnightly dose is approx half the monthly doseContraindications and Precautions: Contraindicated in patients with uncontrolled hypertension or known hypersensitivity to the active substance or any excipient. Should not be used in patients < 18 years. Cardiovascular and thrombotic events; monitor and control BP; hypertensive encephalopathy seizures; pure red cell aplasia (PRCA); use with caution in patients with epilepsy, haemoglobinopathies or platelet levels > 500 x 109/L; monitor iron status; Vitamin B, folic acid or iron deficiencies, chronic blood loss, bone marrow fibrosis, haemolysis and severe aluminium overload may compromise the effectiveness of therapy. Adverse Effects: Hypertension; diarrhoea; nasopharyngitis; upper respiratory tract infection; headache; procedural hypotension; muscle spasms; back pain; cough; fluid overload. Post-marketing: PRCA. Please review the full Product Information before prescribing, available on request from Roche Products Pty Limited (www.roche-australia.com/productinfo/mircera). Reference: 1. MIRCERA Approved Product Information. Available at: www.roche-australia.com/productinfo/mircera. Further information is available from Roche Products Pty Limited, ABN 70 000 132 865, Level 8, 30-34 Hickson Road, Sydney NSW 2000. Medical Information: 1800 233 950. ®Registered Trademark. EMVMIR0180 MN37561530 PreparedAug17.
PBS Information: This product is listed on the PBS as a Section 100 item. Refer to PBS Schedule for full authority information.
23DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
0930-1030 Seminar 2 Basic Science & Mini Orals Session 2
Seminar 2: Basic Science; Diabetes
Waterfront 1
Mini Orals Waterfront 2Experimental
Immunology and Developmental
Biology
Mini OralsWaterfront 3Paediatric and
Pregnancy Associated
Chairs: Josephine Forbes & Melinda Coughlan
Helen Healy & Aaron Chakera
Peter Trnka & Shilpa Jesudason
0930-0950 THE ROLE OF OXIDATIVE STRESS IN DIABETIC NEPHROPATHY
Karin Jandeleit-Dahm
THE IMPACT OF INTRAUTERINE INFLAMMATION ON FETAL RENAL DEVELOPMENT
Megan Sutherland
SCOPE AND CONSISTENCY OF OUTCOMES REPORTED IN RANDOMISED TRIALS CONDUCTED IN CHILDREN WITH CHRONIC KIDNEY DISEASE
Camilla Hanson
RENAL EXPRESSION OF TOLL-LIKE RECEPTORS IN PATIENTS WITH CRESCENTIC GLOMERULONEPHRITIS
Kim Maree O’Sullivan
MITOCHONDRIAL DYSFUNCTION DEFINES A POPULATION OF YOUNG PEOPLE WITH TYPE 1 DIABETES AT RISK OF KIDNEY DISEASE
Nikki Isbel
0950-1010 METABOLIC MEMORY AND HYPOXIC MEMORY: EPIGENETICS IN DIABETIC NEPHROPATHY
Masaomi Nangaku*
INTERLEUKIN (IL)-17 PRODUCTION BY TUBULOINTERSTITIAL HUMAN GAMMA-DELTA T CELLS IN RENAL FIBROSIS AND CHRONIC KIDNEY DISEASE
Andrew Kassianos
NEUROCOGNITIVE AND EDUCATIONAL OUTCOMES IN CHILDREN AND ADOLESCENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Kerry Chen
24 ANZSN | ANNUAL SCIENTIFIC MEETING
DEVELOPMENT OF MONOCLONAL ANTIBODIES FOR USE IN A NEW MOUSE MODEL OF VASCULITIS
Holly Hutton
PRE-ECLAMPSIA IS ASSOCIATED WITH CHANGES IN THE ABUNDANCE AND PHOSPHORYLATION OF SODIUM TRANSPORTERS IN URINARY EXOSOMES
Peter Mount
1010-1030 NOVEL THERAPIES BASED ON THE PATHOPHYSIOLOGY OF DIABETIC NEPHROPATHY
Carol Pollock
FLT3 INHIBITOR ATTENUATES RENAL INJURY IN ADRIAMYCIN NEPHROPATHY BY SUPPRESSING CD103+ DC-MEDIATED T CELL ACTIVATION
Padmashree Rao
EFFECT OF PLACENTAL GROWTH FACTOR ON TROPHOBLAST INTEGRATION INTO ENDOTHELIAL CELL NETWORKS
Katrina Chau
LOCALLY SECRETED ICOS-IG PROLONGS SURVIVAL OF XENOGRAFTS AND ALLOGRAFTS
Francesco Ierino
SOCIOECONOMIC STATUS AND HEALTH IN CHILDREN AND ADOLESCENTS WITH CHRONIC KIDNEY DISEASE – THE KIDS WITH CKD STUDY (KCAD)
Madeleine Didsbury
A PHASE 1 STUDY OF MESENCHYMAL STROMAL CELLS AND ISCHAEMIA REPERFUSION INJURY IN DECEASED DONOR RENAL TRANSPLANTATION
Ashley Irish
INTRAUTERINE GROWTH RESTRICTION: ADVERSE EFFECTS ON RENAL GROWTH AND FUNCTION IN PRETERM INFANTS
Megan Sutherland
EARLY POSTNATAL IMPAIRMENT OF RENAL FUNCTION IN INDIGENOUS INFANTS BORN PRETERM
Megan Sutherland
25DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
1030-1100 Morning Tea Exhibition Area, Hall 2-3, Ground Level, DCCRenal Scientists Meeting Meeting Room 3
Ground Level, DCC
1100-1200 Trainee Prize & Mini Orals Session 3
Shaun Summers Clinical Trainee Prize Session
Waterfront 1
Mini OralsWaterfront 2
Haemodialysis General and Access / Peritoneal Dialysis
Mini OralsWaterfront 3Experimental
Tubulointersitital / Acute Kidney Injury
Chair: Francesco Ierino Chairs: Robert MacGinley & Tracey
Putt
Chairs: Wendy Hoy & Jay Chandra
UTILITY OF KIDNEY BIOPSY IN PATIENTS WITH SIGNIFICANT PROTEINURIA IN THE NON-NEPHROTIC RANGE
Richard Germann
THE PERSPECTIVES OF HEALTHCARE PROVIDERS ON THE NUTRITIONAL MANAGEMENT OF PATIENTS ON HAEMODIALYSIS: AN INTERVIEW STUDY
Jessica Stevenson
INCREASED FIBROSIS IN ACC KNOCKIN MICE FOLLOWING RENAL INJURY CONFIRMS A PATHOGENIC ROLE FOR REDUCED FATTY ACID OXIDATION
Mardiana Lee
ATYPICAL HAEMOLYTIC URAEMIC SYNDROME IN AUSTRALIA: REAL-WORLD CHALLENGES AND LESSONS FROM THE THROMBOTIC MICROANGIOPATHY REGISTRY
Kate Robson
IDENTIFYING THE CRITICAL DIMENSIONS OF FATIGUE FOR A CORE OUTCOME MEASURE FOR TRIALS IN HAEMODIALYSIS: AN INTERNATIONAL SURVEY
Angela Ju
EPIGENETIC MODIFICATIONS TO H3K9 IN RENAL TUBULOINTERSTITIAL CELLS AFTER UNILATERAL URETERIC OBSTRUCTION AND TGF-BETA1 STIMULATION
Tim Hewitson
BIOCHEMICAL COMPARISON OF 8-HOUR HAEMODIALYSIS AND 4-HOUR HAEMODIAFILTRATION, AND TWO DIALYSIS MEMBRANES
Shi Zhou Choo
REPEATED SUBCLINICAL BLOOD-PRESSURE VOLATILITY DEMONSTRATED BY CONTINUOUS MONITORING DURING CONVENTIONAL OUTPATIENT HAEMODIALYSIS
Jacqui Evans, Scott Wilson
ROLE OF NADPH-OXIDASE NOX5 IN HUMAN DIABETIC NEPHROPATHY
Jay Jha
26 ANZSN | ANNUAL SCIENTIFIC MEETING
COMPARING PATIENT SURVIVAL ON HAEMODIAFILTRATION AND HAEMODIALYSIS: AN ANZDATA REGISTRY STUDY
Emily See
REPORT OF THE STANDARDISED OUTCOMES IN NEPHROLOGY-HAEMODIALYSIS (SONG-HD) CONSENSUS WORKSHOP ON ESTABLISHING A CORE OUTCOME MEASURE FOR VASCULAR ACCESS IN HAEMODIALYSIS
Andrea Viecelli
CHRONIC FETAL HYPOXIA LEADS TO LONG-TERM PROXIMAL TUBULE INJURY IN THE SHEEP KIDNEY
Megan Sutherland
THE EFFECT OF LARGE BODY WEIGHTS ON PD OUTCOMES
Mahmoud Amer
VASCULAR ACCESS OUTCOMES REPORTED IN RANDOMISED TRIALS CONDUCTED IN PATIENTS REQUIRING HAEMODIALYSIS: A SYSTEMATIC REVIEW
Andrea Viecelli
MODULATION OF UPREGULATED TRANSCRIPTIONAL SIGNALING PATHWAYS IN RODENT DIABETIC NEPHROPATHY AFTER TREATMENT WITH A NOVEL ANTI-FIBROTIC AGENT FT011: CORRELATES WITH HUMAN DIABETIC KIDNEY DISEASE
Robyn Langham
ASSOCIATION BETWEEN CAUSES OF PERITONEAL DIALYSIS TECHNIQUE FAILURE AND ALL-CAUSE MORTALITY
Jenny HC Chen
OUTCOMES OF SUBCUTANEOUSLY BURIED PERITONEAL DIALYSIS CATHETERS BETWEEN 2006 AND 2014 AT ROYAL DARWIN HOSPITAL
Thwe Thwe Soe
RENAL TUBULAR EPITHELIAL CELL ISOMETRIC VACUOLATION ASSOCIATED WITH SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITOR USE: A CASE REPORT
Beata Zahorowska
FATHERHOOD WHILE RECEIVING DIALYSIS AND AFTER KIDNEY TRANSPLANTATION: ANALYSIS OF THE AUSTRALIAN AND NEW ZEALAND DIALYSIS AND TRANSPLANTATION (ANZDATA) REGISTRY, 1970-2014
Alyssa Fitzpatrick
ASEPTIC TECHNIQUE MAINTAINS STERILITY OF ANTIBIOTIC-LOADED PERITONEAL DIALYSIS FLUID
Louis Huang
ACTIVATED CD47 PROMOTES ACUTE KIDNEY INJURY BY LIMITING AUTOPHAGY
Natasha Rogers
27DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
IMPACT OF BELATACEPT CONVERSION ON KIDNEY TRANSPLANT FUNCTION, HISTOLOGY AND GENE EXPRESSION
Pooja Sanghi
PD BUDDY: USING SMARTPHONE TECHNOLOGY TO IMPROVE PATIENT CARE
Marnie Budd, Robyn Rogers
RENAL SAFETY OF A SHORT COURSE OF GENTAMICIN IN ELDERLY PATIENTS (THE REGENT STUDY)
Christopher Sia
1205-1305 ANZDATA & Mini Orals Session 4
ANZDATAWaterfront 1
Mini Orals Waterfront 2Experimental
Tubulonterstitial / Acute Kidney Injury
Mini OralsWaterfront 3
Cardiovascular / Hypertension / CKD-Mineral Bone Disease/
Anaemia/Adequacy
Chair: Matthew Jose Chairs: Andrew Mallett &
Poh Yi Gan
Chairs: Suetonia Palmer & Murali Gangadharan
Komala
ANZDATA overviewMatthew Jose
RIPK1 INHIBITION ALLEVIATES RENAL FIBROGENESIS
Ying Shi
BLOOD PRESSURE AND RESPIRATORY SYMPATHETIC MODULATION IN AN ANIMAL MODEL OF CHRONIC KIDNEY DISEASE AFTER BILATERAL CAROTID SINUS DENERVATION
Manash Saha
Patient Reported Outcome MeasuresAndy Salmon
ANALYSIS OF APICAL AND BASOLATERAL SECRETED EXOSOMES FROM HUMAN PROXIMAL TUBULE EPITHELIAL CELLS (PTEC) UNDER NORMAL AND DISEASED CONDITIONS
Xiangju Wang
LIPID-LOWERING THERAPY AMONG CKD PATIENTS IN AUSTRALIAN GENERAL PRACTICE
Masuma Khanam
TRANSIENT INCREASE IN WATER INTAKE IS SUFFICIENT TO REDUCE LONGTERM CARDIORENAL PROGRESSION IN LPK RATS
Priyanka Sagar
A RARE CASE OF GENE CYP11B1 DEFICIENCY CAUSING HYPERALDOSTERONISM
Masnun Kayes
For nearly half a century we have been helping patients with end stage renal disease live fuller, richer and more active lives. We are committed to life and to life-changing outcomes.
Fresenius Medical Care - www.fmc-au.com
29DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
USING THE GEOMETRIC FRAMEWORK TO EXPLORE THE LONGITUDINAL EFFECTS OF DIETARY MACRONUTRIENT CONSUMPTION ON MARKERS OF KIDNEY AGEING
Josephine Forbes
A NOVEL AND UNIQUE PROTEIN I-BODY AD-114 INHIBITED TGFβ1-INDUCED EXPRESSION OF FIBRONECTIN AND COLLAGEN 4 IN RENAL PROXIMAL TUBULAR CELLS
Qinghua Cao
Transplant wait listing and organ utilisationMatthew Sypek
A NOVEL LONG NON-CODING RNA (LNCRNA) IN DIABETIC KIDNEY DISEASE
Sanela Redzepagic
CHANGES IN BONE AND MINERAL METABOLISM MARKERS AFTER CESSATION OF CINACALCET IN DIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM
Irene Ruderman
ELEVATED SERUM CREATININE AND ACUTE KIDNEY INJURY FOLLOWING RADICAL TUMOUR NEPHRECTOMY
Robert Ellis
DETERIORATION OF CORTICAL BONE MICROARCHITECTURE IN RENAL OSTEODYSTROPHY – UNDER-REPRESENTED IN THE ‘TURNOVER MINERALISATION VOLUME’ (TMV) CLASSIFICATION?
Ashish Sharma
Examination of Centre Effects using the ANZDATA RegistryCarmel Hawley
USING THE KINETIC EGFR FORMULA FOR DETECTING AKI AND ESTIMATING GFR IN THE NON ICU SETTING
Faith See Huiwen
EFFECTIVE SOLUTE CLEARANCE KINETICS ACROSS SEQUENTIAL HIGH-FLUX HAEMODIALYSIS (HD) TREATMENTS BY TIME-SERIES ANALYSIS OF FREQUENTLY SAMPLED EFFLUENT DIALYSATE ALIQUOTS
Ryan Slack, Scott Wilson
β-CATENIN/FOXO PROTECTS AGAINST KIDNEY FIBROSIS
Padmashree Rao
Lunch Exhibition Area, Hall 2-3, Ground Level, DCCKHA-CARI Indigenous Guidelines Meeting Room 3
Ground Level, DCC
30 ANZSN | ANNUAL SCIENTIFIC MEETING
1400-1530 Seminar 3 & Basic Science Award
Seminar 3: Clinical ScienceAuditorium 2
Basic Science AwardWaterfront
Chairs: Alan Cass & William Majoni Natasha Rogers
1400-1430 DIALYSIS MODALITIES
Charmaine LokBIOLOGICALS TARGETING CYTOKINES INDUCING CD4+ TH CELL SUBSET DIFFERENTIATION FOR THE TREATMENT OF EXPERIMENTAL ANTI-MPO GN
Poh-Yi Gan
IL-33 EXACERBATES IGA GLOMERULONEPHRITIS IN B CELL ACTIVATING FACTOR (BAFF) TRANSGENIC MICE
Yuan Min Wang
1430-1500 TRAVEL MEDICINE FOR TRANSPLANT PATIENTS (“THE ICING ON THE CAKE”)
Camille Kotton
CYCLOPHILIN INHIBITION PREVENTS SEVERE RENAL ISCHAEMIA/REPERFUSION INJURY
Khai Gene Leong
A PERIPHERALLY ACTING CANNABINOID RECEPTOR 1 ANTAGONIST SUPPRESSES RENAL INTERSTITIAL FIBROSIS
David Nikolic-Paterson
1500-1530 AGING AND THE KIDNEYS
Motoko Yanagita*
DOMINANT HLA-MEDIATED PROTECTION FROM THE RISK OF AUTOIMMUNE RENAL DISEASE IS CONFERRED BY ANTIGEN-SPECIFIC REGULATORY CELLS
Joshua Ooi
FOLLISTATIN MODULATES ISCHAEMIA-REPERFUSION-INDUCED RENAL FIBROSIS IN MICE
Doreen Fang
1530-1600 Afternoon Tea Exhibition Area, Hall 2-3, Ground Level, DCC
31DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
1600-1745 Mini Orals Session 5
Mini OralsWaterfront 1
Transplantation
Mini OralsWaterfront 2
General Nephrology
Mini OralsWaterfront 3
Epidemiology / Health Services
Chairs: Katherine Barraclough & Michael Collins
Chairs: Muh Geot Wong & Andrew McNally
Chairs: Martin Gallagher & Paul Lawton
NOVEL HLA ALLELES AND EPLET MISMACTHES IN INDIGENOUS RENAL TRANSPLANT RECIPIENTS
Ankit Sharma
EFFECTS OF DIMETHYL FUMARATE ON RENAL MACROPHAGE ACCUMULATION AND CYST GROWTH IN EXPERIMENTAL POLYCYSTIC KIDNEY DISEASE
Oliver Oey
ISCHAEMIC HEART DISEASE MORTALITY IN PEOPLE WITH END STAGE KIDNEY DISEASE IN AUSTRALIA AND NEW ZEALAND: A COHORT STUDY FROM 1980 TO 2013
Angela Webster
SPECIFIC DETECTION OF GRAFT DERIVED DNA IN THE PLASMA DURING ANTIBODY MEDIATED REJECTION: DEVELOPMENT OF A NEW DIAGNOSTIC TOOL
John Whitlam
PILOT STUDY: URINARY INDOXYL SULPHATE AS A PREDICTOR OF POSTOPERATIVE KIDNEY FUNCTION FOLLOWING RADICAL TUMOUR NEPHRECTOMY
Robert Ellis
THE HEALTHTRACK STUDY- A RANDOMISED CONTROL TRIAL OF INTERDISCIPLINARY CARE ON WEIGHT LOSS 12 MONTH FOLLOW UP
Maureen Lonergan
INVESTIGATING ANAL NEOPLASIA IN KIDNEY TRANSPLANT RECIPIENTS: A CROSS-SECTIONAL PILOT STUDY
Angela Webster
BOWEL HABITS AND THE ASSOCIATION WITH SERUM P-CRESYL SULFATE IN CKD PATIENTS
Christiane Ramos
MORTALITY OUTCOMES FOR MĀORI AND NON-MĀORI AFTER COMMENCING RENAL REPLACMENT THERAPY IN AOTEAROA/NEW ZEALAND: A KAUPAPA MĀORI APPROACH
Suetonia Palmer
* APSN SPEAKER
32 ANZSN | ANNUAL SCIENTIFIC MEETING
THE LIVED EXPERIENCE OF ‘BEING EVALUATED’ FOR ORGAN DONATION: FOCUS GROUPS WITH LIVING KIDNEY DONORS
Camilla Hanson
AN EXTRACTION TOOL FOR CHRONIC KIDNEY DISEASE DATA FROM AUDIT4
Wendy E Hoy
DECISION-MAKING AMONG CALD ADULTS WITH CHRONIC DISEASE: A SYSTEMATIC REVIEW OF BARRIERS, FACILITATORS, AND INTERVENTIONS
Danielle Muscat
COMPARISON OF U.K. AND U.S. KIDNEY DONOR RISK INDICES (KDRIS) IN THE AUSTRALIAN AND NEW ZEALAND POPULATION
Kathryn Dansie
ANTHROPOMETRIC PROFILE IN INDIGENOUS AUSTRALIANS IN THE EGFR STUDY
Camilla Feeney
RENAL SUPPORTIVE CARE: CURRENT EXPERIENCES IN VICTORIA
Kathryn Ducharlet
ANAEMIA IN KIDNEY TRANSPLANT RECIPIENTS IN THE FIRST YEAR
Andy Lim
ENDOTHELIAL GLYCOCALYX DAMAGE IN KIDNEY DISEASE IS REFLECTED BY SERUM BIOMARKERS BUT NOT THE PERFUSED BOUNDARY REGION
Hui Liew
DECISION-MAKING ACROSS THE CKD TRAJECTORY: A QUALITATIVE INTERVIEW STUDY WITH CALD PATIENTS
Danielle Muscat
INCREASED RECRUITMENT OF LYMPHOCYTE SUBSETS IN HUMAN KIDNEY TRANSPLANT REJECTION
Katrina Kildey
WHAT ARE THE INFECTIONS THAT AUSTRALIANS ON RENAL REPLACEMENT THERAPY DIE FROM?
Alison Graver
PATIENT PREFERENCES FOR DIALYSIS MODALITIES: A DISCRETE-CHOICE EXPERIMENT
Rachael Walker
TIME COURSE AND RATES OF REJECTION IN ATSI RENAL TRANSPLANT RECIPIENTS
Ramyasuda Swaminathan
EXPRESSION OF URINARY MICRORNAS AS NOVEL DIAGNOSTIC BIOMARKERS FOR DIABETIC KIDNEY DISEASE
Qinghua Cao
CHRONIC KIDNEY DISEASE (CKD) MONITORING IN AUSTRALIAN GENERAL PRACTICE
Masuma Khanam
END STAGE KIDNEY DISEASE RISK PROFILE IN LIVING KIDNEY DONORS FOR PAEDIATRIC VERSUS ADULT KIDNEY TRANSPLANT RECIPIENTS IN AUSTRALIA AND NEW ZEALAND
Matthew Roberts
PHARMACOKINETICS OF METFORMIN IN SETTING OF CKD
Tracey Putt
THE DIALYSIS MODELS OF CARE PARTNERSHIP: LINKING HOSPITAL ADMINISTRATIVE AND ANZDATA REGISTRY DATA FOR NORTHERN TERRITORY (NT) RENAL REPLACEMENT THERAPY (RRT) RECIPIENTS
Shamsir Ahmed
33DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
TWENTY YEARS EXPERIENCE OF RENAL TRANSPLANTATION FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM). RISK FACTORS THAT INFLUENCE GRAFT AND PATIENT SURVIVAL
David Goodman
PREVALENCE OF SARCOPENIA IN PATIENTS ON DIALYSIS AND THE CORRELATION BETWEEN MUSCLE STRENGTH, MUSCLE MASS AND FUNCTION AS DETERMINANTS OF SARCOPENIA IN THE DIALYSIS POPULATION
Muralikrishna Gangadharan Komala
BLOOD PRESSURE MANAGEMENT IN HYPERTENSIVE PATIENTS WITH NON-DIALYSIS CHRONIC KIDNEY DISEASE IN QUEENSLAND, AUSTRALIA
Jenny Zhang
TRANSPLANT ASSOCIATED THROMBOTIC MICROANGIOPATHY IN NON-RENAL SOLID ORGAN TRANSPLANT PATIENTS: A CASE SERIES
Brian Doucet
TREATMENT PARADIGM IN A YOUNG MALE WITH GERM CELL TUMOUR WITH WORSENING IGA NEPHROPATHY
Samuel Chan
WHAT A PATIENT WANTS: A CONSUMER PERSPECTIVE OF KIDNEY SUPPORTIVE CARE
Louise Purtell
THE IMPACT OF DE NOVO VASCULAR DISEASE IN LIVE DONOR KIDNEY TRANSPLANT RECIPIENTS
Rahul Mainra
CUMULATIVE RADIATION EXPOSURE AMONGST RENAL REPLACEMENT THERAPY PATIENTS IN THE NORTHERN TERRITORY – A RETROSPECTIVE COHORT STUDY
Mohd Azlan Mohd Hashim
PARTICIPANT CHOICES TOWARDS RECEIVING POTENTIAL INCIDENTAL GENETIC FINDINGS IN AN AUSTRALIAN NEPHROLOGY RESEARCH GENOMICS STUDY
Andrew Mallett
VACCINE PREVENTABLE DISEASE IN IMMUNOSUPPRESSED PEOPLE WITH KIDNEY DISEASE
Alison Graver
ELICITING THE PRIORITIES OF PATIENTS, CAREGIVERS AND HEALTH PROFESSIONALS FOR IMPORTANT OUTCOMES IN NEPHROLOGY USING INTERNATIONAL BEST-WORST SCALING SURVEYS
Martin Howell
1745 Sessions Close
1900 till late
ANZSN ASM Sunset Dinner DCC ForecourtFull delegates inclusive, additional tickets can be purchased for guests and day delegates for $160. Bookings essential!
34 ANZSN | ANNUAL SCIENTIFIC MEETING
WEDNESDAY 6TH SEPTEMBER 2017 – ANZSN ASM 20170800 Registration Desk Open Concourse,
Ground Level, DCC
0800 Speakers Preparation Room Meeting Room 4 Ground Level, DCC
Seminar 4 – Clinical ScienceAuditorium 2
Indigenous Patient Voices Symposium
Meeting Room 2, Ground Level
Chairs: Jaqui Hughes & Steve May
0830-0900 BK INFECTION IN KIDNEY TRANSPLANT RECIPIENTS
Basu Gopal*
PATIENTS & CARERS YARNING CIRCLE
(closed session: clinicians/policymakers not invited)• Welcome to Country• Introductions• Sharing stories• Understanding common themes (facilitated)• What is to be presented?Proudly supported by Kidney Health Australia and Astellas.
0900-0930 FINDINGS FROM THE HEMODIALYSIS FISTULA STUDY
Laura Dember
0930-1100 ANZPNA AGM | Meeting Room 3
Plenary 3Auditorium 2
Chair: Kevan Polkinghorne
0930-1030 Plenary Speaker: Charmaine LokINSIGHTS AND INNOVATION IN VASCULAR ACCESS
1030-1130 Substantial Brunch Exhibition Area, Hall 2-3 Ground Level, DCC
1130 ASM ends. Exhibition Bump-Out Commences
35DARWIN, NT | 4 – 6 SEPTEMBER 2017
PR
OG
RA
M
Paediatric Nephrology Update CourseMeeting Room 3, Ground Level
Indigenous Patient Voices SymposiumMeeting Room 2, Ground Level
1200-1215 Registration & Welcome Dr Joshua Kausman President of ANZPNA
1100-1300 Presentations by Patients and/or Carers15 minutes each (open to all delegates)
1215-1245 EVIDENCE BASED MANAGEMENT OF NEPHROTIC SYNDROME IN CHILDREN
Dr Steven McTaggart Lady Cilento Children’s Hospital, Brisbane
1245-1330 THE DIAGNOSIS AND MANAGEMENT OF HAEMOLYTIC UREMIC SYNDROME IN 2017
Dr Joshua Kausman The Royal Children’s Hospital, Melbourne
1300-1330 Break 1 Concourse
1330-1400 CONGENITAL ANOMALIES OF THE KIDNEY AND URINARY TRACT: RED FLAGS AND CALLING CRITERIA
Dr Sean Kennedy, University of New South Wales, Sydney
1330-1500 Facilitated discussion of themes arising from patient/carer presentations, with clinician & policy maker input.
1400-1415 Break Concourse
1415-1445 ACUTE POST STREPTOCOCCAL GLOMERULONEPHRITIS: UPDATE ON CHANGING EPIDEMIOLOGY AND ACUTE MANAGEMENT
Dr Swasti Chaturvedi, Royal Darwin Hospital, Darwin
1500-1530 Break 2 Concourse
* APSN SPEAKER
36 ANZSN | ANNUAL SCIENTIFIC MEETING
1445-1515 WHAT’S CURRENT IN CHILDHOOD SLE?
Dr Fiona Mackie, Sydney Children’s Hospital, Sydney
1530-1700 Facilitated “solutions brainstorming” discussion (all involved)
1515-1545 CHILDHOOD DETERMINANTS OF ADULT KIDNEY DISEASE
Dr Gurmeet Singh, Menzies School of Health Research, Darwin
1545-1645 Case Based DiscussionsRegistrants and speakers
1700 Meeting Closes 1700-1730 Travel to NT Parliament House
1730-1900 Parliamentary Reception with NT Minister for Health, Natasha Fyles MLANT Parliament House
Australian and New Zealand Society of Oaks Elan Interventional Nephrology (ANZSIN) Meeting
Wednesday 6 to Friday 8 September 2017 Oaks Elan, Darwin
WIRELESSNETWORK NAME: ANZSN ASM
PASSWORD: anzsnasm
C
M
Y
CM
MY
CY
CMY
K
HDF_Performance_And_Beyond_A4_Portrait.pdf 1 14/08/2017 3:40:55 PM
38 ANZSN | ANNUAL SCIENTIFIC MEETING
ACUTE KIDNEY INJURY
01 GEMCITABINE INDUCED HEMOLYTIC URAEMIC SYNDROME SUCCESSFULLY TREATED WITH ECULIZUMAB – A CASE REPORT
Muralikrishna Gangadharan Komala
02 UNUSUAL PRESENTATION OF BILATERAL RENAL ARTERY STENOSIS AS ANURIC RENAL FAILURE WITH SUCCESSFUL STENTING
Geoff Harley
03 EPIDEMIOLOGY AND COSTS OF MANAGEMENT OF ACUTE KIDNEY INJURY IN A TERTIARY CARE CENTER IN AUSTRALIA
Sanjeeva Herath
04 SOFA COAGULATION SCORE AND PATIENT OUTCOMES IN SEVERE ACUTE KIDNEY INJURY: ANALYSIS FROM THE RANDOMISED EVALUATION OF NORMAL VERSUS AUGMENTED LEVEL (RENAL) STUDY
Jin Lin
05 RENAL CONSULT AUDIT AT A TERTIARY REFERRAL HOSPITAL Charlotte Ogilvy
06 A CASE OF ACUTE KIDNEY INJURY AND THROMBOTIC MICROANGIOPATHY SECONDARY TO UROTHELIAL CANCER AND THE IMPACT OF TREATMENT ON THE DISEASE PROCESS
Ben Talbot
07 “UNEARTHING” THE CAUSE OF ACUTE KIDNEY INJURY IN A GARDENER
Jeffrey Wong
08 PATIENT-DERIVED ENDOTHELIAL CELL FUNCTION IS PREDICTED BY CONTROLLED BLOOD PRESSURE
Brooke Huuskes
09 RATES AND CHARACTERISTICS OF ACUTE KIDNEY INJURY (AKI) IN THE CHRONIC KIDNEY DISEASE IN QUEENSLAND (CKD.QLD) REGISTRY
Gregory Wilson
10 ETHYLENE GLYCOL TOXICITY – A RARE CAUSE OF HIGH ANION GAP METABOLIC ACIDOSIS IN AUSTRALIA
Gregory Wilson
EPIDEMIOLOGY AND PUBLIC HEALTH
11 ACUTE INTERSTITIAL NEPHRITIS (AIN) IN AUSTRALIA: A SINGLE CENTRE CASE SERIES
Gregory Wilson
12 TRAJECTORIES OF EGFR DECLINE OVER A FOUR YEAR PERIOD: THE EGFR FOLLOW UP STUDY
Federica Barzi
POSTERS
39DARWIN, NT | 4 – 6 SEPTEMBER 2017
PO
STE
RS
13 EVALUATING ASSOCIATIONS OF BODY MASS INDEX (BMI) IN CHRONIC KIDNEY DISEASE PATIENTS (CKD) IN THE CKD.QLD REGISTRY; QUEENSLAND, AUSTRALIA
Samuel Chan
14 DEATH FROM STROKE IN THE ESKD POPULATION; A COHORT STUDY IN AUSTRALIA AND NEW ZEALAND, 1980-2013
Nicole L De La Mata
15 KNOWLEDGE ABOUT CHRONIC KIDNEY DISEASE IN THE AUSTRALIAN PUBLIC, USING A NEW VALIDATED QUESTIONNAIRE
Pankti Gheewala
16 ELDERLY DIALYSIS PATIENTS AND QUALITY OF LIFE: A SINGLE CENTRE EXPERIENCE
Krystal Harrison
17 DISTANCE TO HUB RENAL SERVICE AND OUTCOMES OF PATIENTS WITH STAGE IV-V CHRONIC KIDNEY DISEASE
Prasanti Kotagiri
18 KIDNEY DISEASE IN INCARCERATED TASMANIANS Stephanie Kuo
19 ATTAINMENT OF HEMOGLOBIN, CALCIUM AND PHOSPHATE TARGETS, MORTALITY AND TIME TO TRANSPLANT IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS IN AUSTRALIA
Dhanusya Sivanthanan
20 RENAL MARKERS AT BASELINE IN THE HEALTHTRACK STUDY- A RANDOMISED CONTROL TRIAL OF INTERDISCIPLINARY CARE ON WEIGHT LOSS
Maureen Lonergan
21 SALT WASTING NEPHROPATHY(SWN) – IMPORTANT QUESTIONS
Rishi Narenthiran
22 SALT WASTING NEPHROPATHY(SWN) IN PRIMARY CARE Rishi Narenthiran
23 THE PREVALENCE OF NON-DIABETIC PATHOLOGY IN THE RENAL BIOPSIES OF PATIENTS WITH DIABETES IN FAR NORTH QUEENSLAND
Lee Skeat
24 CHARACTERISTICS, MORTALITY AND RENAL OUTCOMES OF PATIENTS WITH DIABETES AND CKD WHO HAVE UNDERGONE RENAL BIOPSY.
Samantha Ng
25 A SINGLE CENTRE EXPERIENCE OF RENAL CALCULI IN CENTRAL AUSTRALIA
Sajan Thomas
26 THE PREVALENCE OF CHRONIC KIDNEY DISEASE AND ACUTE KIDNEY INJURY AMONGST ADULT ACUTE INPATIENTS AT MONASH HEALTH.
Dan Tran
27 CKD.QLD: RELATIONSHIP BETWEEN SMOKING AND CHRONIC KIDNEY DISEASE (CKD) IN THE DARLING DOWNS REGION, QUEENSLAND.
Wendy Hoy
40 ANZSN | ANNUAL SCIENTIFIC MEETING
28 PREVALENCE AND SEROCONVERSION OF HEPATITIS C VIRUS AMONG HEMODIALYSIS PATIENTS IN PEMALANG,INDONESIA
Muchamad Nur Aziz
29 APPROPRIATENESS OF NEPHROLOGY REFERRALS IN REGIONAL AUSTRALIA: IMPLICATIONS FOR A SPECIALIST SERVICE
Rebecca Thwaites
30 MEDICATION BURDEN, ADHERENCE AND HEALTH-RELATED QUALITY OF LIFE IN ADVANCED CHRONIC KIDNEY DISEASE
Wubshet Tesfaye
CARDIOVASCULAR/HYPERTENSION
31 SUDDEN SEVERE HYPERTENSION: AN ATYPICAL MANIFESTATION OF PRIMARY HYERPARATHYROIDISM. A CASE REPORT
Claudia Ferrier
32 RENAL ARTERY STENOSIS AS A CAUSE OF TAKOTSUBO CARDIOMYOPATHY
Victoria Sasongko
33 FIRST CARDIOVASCULAR EVENT POST ENROLMENT IN CKD.QLD REGISTRY PATIENTS WITH DIABETES WHO HAVE UNDERGONE RENAL BIOPSY
Ken-soon Tan
34 HIGH-SENSITIVITY CARDIAC TROPONIN T AND C-REACTIVE PROTEIN HAVE DIFFERENT PROGNOSTIC VALUES IN HAEMO- AND PERITONEAL DIALYSIS POPULATION: A COHORT STUDY
Titi Chen
GLOMERULONEPHRITIS
35 RENAL CD141+ DENDRITIC CELLS INFILTRATION IN CRESCENTIC GLOMERULONEPHRITIS IN HUMAN AND MICE
Padmashree Rao
36 RENAL CD141+ DENDRITIC CELL INFILTRATION IN IGA NEPHROPATHY
Padmashree Rao
37 COMPLICATED ATRIAL THROMBUS IN RENAL TRANSPLANT RECIPIENT WITH RECURRENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Nyi Aung
38 PREVALENCE OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE IN PATIENTS UNDERGOING DIAGNOSTIC RENAL BIOPSY
Ke Li Chow
39 A CASE REPORT OF HENOCH-SCHONLEIN PURPURA AND IGA NEPHROPATHY ASSOCIATED WITH RIVAROXABAN
Edmund Chung
40 A CASE OF ANTI-GBM BEHAVING DIFFERENTLY Sanduni Fernando
41 A CASE OF METHAMPHETAMINE-RELATED IMMUNE COMPLEX GLOMERULONEPHRITIS WITH INTENSE INTERSTITIAL INFLAMMATION
Sarah Gleeson
41DARWIN, NT | 4 – 6 SEPTEMBER 2017
PO
STE
RS
42 OTITIS MEDIA WITH ANCA – ASSOCIATED VASCULITIS: A CASE FROM TASMANIA
Alison Graver
43 CLINICAL AUDIT OF HISTOLOGY BASED RENAL DISEASES IN DARLING DOWNS HEALTH REGION
Vinod Khelgi
44 MEMBRANOUS NEPHROPATHY AND MALIGNANCY-A REPORT FROM DARLING DOWNS HOSPITAL AND HEALTH SERVICE
Vinod Khelgi
45 PREVALENCE OF ANCA VASCULITIS IN DDHHS POPULATION Vinod Khelgi
46 THE MAN WHO ‘CRIED’ WOLF: CRYOGLOBULINEMIC GLOMERULONEPHRITIS ASSOCIATED WITH T CELL LYMPHOMA
Jennifer Li
47 PARANEOPLASTIC IMMUNOGLOBULIN A NEPHROPATHY AND ASSOCIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS IN ASYMPTOMATIC LOW VOLUME B-CELL LYMPHOMA
Andrew Mallett
48 C1Q DEPOSITION IN A CASE SERIES OF CHILDREN WITH HENOCH-SCHÖNLEIN PURPURA AND POSITIVE STREPTOCOCCAL SEROLOGY
Ashlene Mckay
49 JEJUNAL ULCERATION DUE TO GRANULOMATOSIS WITH POLYANGITIS
Daniela Potter
50 ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE AND THE EYE
Daniela Potter
51 IGA-MEDIATED ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE
Amanda Siriwardana
52 A RETROSPECTIVE ANALYSIS OF LUPUS NEPHRITIS IN THE INDIGENOUS AND NON-INDIGENOUS POPULATIONS IN THE NORTHERN TERRITORY: TREATMENT, OUTCOMES AND CHALLENGES
Priyanka Subramani
53 WARFARIN VS NEW ORAL ANTICOAGULANT IN PRIMARY ADULT NEPHROTIC SYNDORME ASSOCIATED VENOUS THORMBOEMBOLISM
Zaw Thet
54 HAEM PIGMENT-INDUCED CHRONIC KIDNEY DISEASE IN A PATIENT WITH GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY
Marina Wainstein
55 ACUTE POST-STREPTOCOCCAL GLOMERULONEPHRITIS- A CASE REPORT AND EPIDEMIOLOGICAL DATA FROM THE NORTHERN TERRITORY OF AUSTRALIA
Swasti Chaturvedi
56 SYSTEMIC LUPUS ERYTHEMATOSUS MASQUERADING AS ATYPICAL HAEMOLYTIC URAEMIC SYNDROME
Stephanie Kuo
42 ANZSN | ANNUAL SCIENTIFIC MEETING
57 PULMONARY FIBROSIS IN RENAL ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) ASSOCIATED VASCULITIS IN TASMANIA OVER A 10 YEAR PERIOD
Stephanie Kuo
HEALTH SERVICES RESEARCH
58 MANAGEMENT OF MEDICATIONS IN PEOPLE WITH CHRONIC KIDNEY DISEASE
Stephanie Kuo, Alison Graver
59 ADVANCED CARE PLANNING IN END-STAGE KIDNEY DISEASE – WE CAN DO BETTER
Margaret Fraenkel
60 ANALYSIS OF LONGITUDINAL CLINICAL DATA TO EVALUATE CHANGES IN THE SCREENING FOR AND MANAGEMENT OF CKD IN SELECT NT PRIMARY HEALTH SERVICES.
Gillian Gorham
61 CHRONIC KIDNEY DISEASE (CKD) AND HEALTH CARE UTILISATION: INSIGHTS FROM HEALTH DATA LINKAGE IN QUEENSLAND
Wendy Hoy
62 PRELIMINARY RESULTS OF AN ECONOMIC EVALUATION OF RESONIUM USE IN ADULTS WITH CHRONIC HYPERKALEMIA
Kelly Lambert
63 DO NORTHERN TERRITORY PATIENTS GET HOME? ANALYSIS THROUGH THE DIALYSIS MODELS OF CARE PARTNERSHIP
Paul Lawton
64 DEVELOPING AN IMPROVED MODEL OF CARE FOR RENAL OUTPATIENTS IN THE NORTHERN TERRITORY (NT)
Kelum Priyadarshana
GENERAL NEPHROLOGY – OTHER
65 RENAL AMYLOIDOSIS: IT’S NOT ALL AL Emily Butler
66 CHRONIC USE OF SODIUM POLYSTYRENE SULFONATE (RESONIUM) ENABLES WIDER IMPLEMENTATION OF RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITION IN CHRONIC KIDNEY DISEASE PATIENTS
Kelly Lambert
67 LIRAGLUTIDE FACILITATES INSULIN MINIMISATION AND WEIGHT LOSS IN PATIENTS WITH ADVANCED KIDNEY DISEASE
Jamie Cheong
68 EFFICACY AND SAFETY OF A MEMBRANE BASED REGIONAL CITRATE ANTICOAGULATION PLASMA EXCHANGE PROTOCOL: AN OBSERVATIONAL, PROSPECTIVE, SINGLE CENTER STUDY
Daniel Christiadi
69 PRE-OPERATIVE EGFR AND LENGTH OF POST-OPERATIVE HOSPITALISATION IN TUMOUR NEPHRECTOMY PATIENTS
Robert Ellis
70 THE UPS AND DOWNS OF BARIATRIC SURGERY: A CASE OF REVERSIBLE OXALATE NEPHROPATHY
Alexandra Gallagher
71 AN AUDIT OF RENAL BIOPSY COMPLICATIONS Alison Graver
43DARWIN, NT | 4 – 6 SEPTEMBER 2017
PO
STE
RS
72 HEPCIDIN RESPONSE TO IV IRON IS DIFFERENT IN CHRONIC KIDNEY DISEASE PATIENTS COMPARED WITH PREGNANCY AND HEALTHY CONTROLS
Louis Huang
73 DENOSUMAB INDUCED HYPOCALCAEMIA IN CHRONIC KIDNEY DISEASE (CKD): PREVENTION IS BETTER THAN TREATMENT
Ryan Jalleh
74 CASE SERIES OF CALCIPHYLAXIS AT DDHHS: SINGLE CENTRE EXPERIENCE
Vinod Khelgi
75 SEROCONVERSION RATES OF HEPATITIS B IN CHRONIC KIDNEY DISEASE AND DIALYSIS COHORTS- A SINGLE CENTRE OBSERVATIONAL STUDY.
Ashani Lecamwasam
76 DNA METHYLATION PROFILING OF GENOMIC DNA ISOLATED FROM URINE IN DIABETIC CHRONIC KIDNEY DISEASE: A PILOT STUDY
Ashani Lecamwasam
77 ENDOTHELIAL GLYCOCALYX DAMAGE IN KIDNEY DISEASE CORRELATES WITH MARKERS OF ENDOTHELIAL DYSFUNCTION
Hui Liew
78 ACUTE RENAL FAILURE, RASH AND DIFFUSE PROLIFERATIVE GLOMERULONEPHRITIS FOLLOWING THREE DOSES OF ETANERCEPT FOR RHEUMATOID ARTHRITIS
Maureen Lonergan
79 A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE USEFULNESS OF GLYCATED HAEMOGLOBIN (HBA1C) AND GLYCATED ALBUMIN AS MEASURES OF BLOOD GLUCOSE LEVELS IN PEOPLE WITH ON DIALYSIS
Sandawana William Majoni
80 RELATIVE VALIDITY OF A BEVERAGE FREQUENCY QUESTIONNAIRE TO ESTIMATE FLUID INTAKE IN CHRONIC KIDNEY DISEASE.
Carly Mannix
81 UNPROVOKED PULMONARY EMBOLISM IN A RENAL TRANSPLANT PATIENT WITH BETA THALASSAEMIA MAJOR
Cathal McGowan
82 COMPLEXITIES OF SYMPTOM MANAGEMENT AND PROGNOSTICATION IN A CASE OF CONSERVATIVELY MANAGED END-STAGE KIDNEY DISEASE (ESKD)
Simon Olenski
83 ESTABLISHING A CHRONIC KIDNEY DISEASE BIOBANK IN QUEENSLAND TO SUPPORT FUTURE RESEARCH
Evan Owens
84 THE DISTINGUISHING RISK OF PROGRESSIVE CHRONIC KIDNEY DISEASE (DROP CKD) STUDY
Evan Owens
85 A CASE OF EVOLVING LUPUS PRESENTING AS REFRACTORY THROMBOTIC MICROANGIOPATHY
Theepika Rajkumar
44 ANZSN | ANNUAL SCIENTIFIC MEETING
86 OBSERVATIONAL CROSS SECTIONAL STUDY INVESTIGATING THE PREVALENCE OF FABRY DISEASE IN CHRONIC STABLE DIALYSIS POPULATION (FIDS).
Gowri Raman
87 THE DIAGNOSIS AND MANAGEMENT OF TAKAYASU’S ARTERITIS IN A REGIONAL SETTING
Joey Lam
88 EVALUATION OF PAIN IN RENAL INTERVENTIONS Victoria Sasongko
89 HEALTH LITERACY IN A SINGLE SITE RENAL SUPPORTIVE CARE CLINIC
Jessica Stevenson
90 SEVERE HYPONATRAEMIA, BEER POTOMANIA AND RHABDOMYOLYSIS
Robert Stonehouse
91 UPDATE ON HOW TELEHEALTH REVOLUTIONISED RENAL HEALTHCARE DELIVERY IN WAIKATO HOSPITAL, NEW ZEALAND
Eddie Tan, Theresa Jennings
92 RENAL TUBERCULOSIS AFTER INTRAVESCIAL BACILLE CALMETTE- GUERIN (BCG) IMMUNOTHERAPY
Zaw Thet
93 INTERIM ANALYSIS OF FABRY TESTING IN WESTERN AUSTRALIA RENAL DIALYSIS PATIENTS: THE FORWARD STUDY
Shamina Akhter
94 DIABETIC MYONECROSIS IN DIABETIC KIDNEY DISEASE Nicholas Trott
95 “INTERVENTIONAL DAY UNIT” – A SOUTH WESTERN SYDNEY LOCAL HEALTH DISTRICT (SWSLHD) OUTPATIENT SERVICE INITIATIVE. REDESIGNING RENAL SERVICE DELIVERY
Jeff Wong
96 THE USUAL DIET OF AN AUSTRALIAN POPULATION OF ADPKD PATIENTS
Jennifer Zhang
97 INFLUENCE OF TIMING AND PATIENT CHARACTERISTICS ON OUTCOMES OF A COMPREHENSIVE PRE-DIALYSIS PROGRAMME IN WESTERN SYDNEY
Lukas Kairaitis
98 TOTAL NEPHRON NUMBER DECREASES WITH THE STAGE OF CHRONIC KIDNEY DISEASE – A STUDY IN JAPANESE SUBJECTS
Go Kanzaki
99 CHARACTERISTICS OF THE SCREENED STUDY POPULATION IN THE PREVENT-ADPKD TRIAL
Annette Wong
HAEMODIALYSIS – CKD-MBD/ANAEMIA/ADEQUACY
100 INDIVIDUALISED FLUID ALLOWANCE CALCULATOR FOR HAEMODIALYSIS PATIENTS
Shi Zhou Choo
101 BROWN TUMOURS MANIFESTING AS MULTIPLE LYTIC LESIONS IN A GENTLEMAN ON DIALYSIS WITH LONGSTANDING UNCONTROLLED HYPERPARATHYROIDISM
Geoff Harley
45DARWIN, NT | 4 – 6 SEPTEMBER 2017
PO
STE
RS
102 IS THE EFFICACY OF NUTRITIONAL VITAMIN D (CHOLECALCIFEROL) COMPARABLE TO ACTIVE VITAMIN D (CALCITRIOL) AS MAINTENANCE THERAPY IN DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE PATIENTS?
Chau Wang Ng
103 MARKED REDUCTION IN USE BUT MINIMAL IMPACT FOLLOWING PBS DELISTING OF CINACALCET IN A TERTIARY INSTITUTION
Yogeshwar Rajaram
104 RETROSPECTIVE OBSERVATIONAL STUDY COMPARING TWO ANAEMIA MANAGEMENT PROTOCOLS FOR PATIENTS ON MAINTENANCE HAEMODIALYSIS
David Langsford
HAEMODIALYSIS – OTHER
105 ELECTROCARDIOGRAPHY (ECG) AND OUTCOME IN PATIENTS ON MAINTENANCE HAEMODIALYSIS
Tony Amin
106 THE VICTORIAN GREENS SURVEY: GAUGING RESPONSES TO ENVIRONMENTAL EFFICIENCIES IN NEPHROLOGY SERVICES
Katherine Barraclough
107 SUCCESSFUL CALCIPHYLAXIS TREATMENT WITH PARENTERAL VITAMIN K
Daniel Christiadi
108 PREVALENCE OF MALNUTRITION AMONGST HAEMODIALYSIS PATIENTS ATTENDING NIGHTCLIFF RENAL UNIT
Christine Cooper
109 EVALUATION OF NUTRITION RESOURCES TARGETED AT AN INDIGENOUS AUDIENCE
Camilla Feeney
110 COMPARING BIOIMPEDENCE SPECTROSCOPY FLUID BALANCE ASSESSMENT TO CLINICAL FLUID BALANCE ASSESSMENT IN HAEMODIALYSIS PATIENTS
Sarah Gleeson
111 LOW RATES OF HEPATITIS B IMMUNITY IN CENTRE HAEMODIALYSIS PATIENTS
Hilton Gock
112 DELAYED RESOLUTION OF AN EXTENSIVE DERMATOPHYTE INFECTION: CLIENT AND CLINICIAN PERCEPTIONS OF TREATMENT RESPONSE IN AN ADULT DEPENDENT ON HAEMODIALYSIS
Jaquelyne Hughes
113 CHARACTERISTICS OF CLIENTS AT INCIDENT HAEMODIALYSIS TREATMENT: A RETROSPECTIVE AUDIT IN A NORTHERN AUSTRALIAN HOSPITAL
Jaquelyne Hughes
114 THE EFFECT OF INTENSIFIED HOME HAEMODIALYSIS TRAINING: A SINGLE CENTRE EXPERIENCE
Graham Stonier, Eddie Tan
46 ANZSN | ANNUAL SCIENTIFIC MEETING
115 A LOCAL EXPERIENCE OF HOW TELEHEALTH REVOLUTIONISED THE ROLE OF RURAL RENAL NURSING
Theresa Jennings, Eddie Tan
116 A SINGLE-CENTRE 12-MONTH RETROSPECTIVE AUDIT OF SATELLITE HAEMODIALYSIS PATIENT ATTENDANCE AND UNUSUED SLOTS
Theresa Jennings
117 THE STANDARDISED OUTCOMES IN NEPHROLOGY-HAEMODIALYSIS (SONG-HD) CONSENSUS WORKSHOP ON ESTABLISHING A CORE OUTCOME MEASURE FOR FATIGUE IN PATIENTS ON HAEMODIALYSIS
Angela Ju
118 IS THERE ANY BENEFIT OF SEASONAL INFLUENZA VACCINATION IN DIALYSIS POPULATION ?
Jola Kapojos
119 ZINC DEFICIENCY AND ASSOCIATED FACTORS IN A COHORT OF HAEMODIALYSIS PATIENTS
Jocelyn King
120 ASSISTED SELF-CARE HAEMODIALYSIS COMPARED TO IN-CENTRE HAEMODIALYSIS – A SINGLE CENTRE EXPERIENCE
Jason Lee
121 THE SYNDROME OF ACUTE BILATERAL BASAL GANGLIA DYSFUNCTION IN DIALYSIS PATIENTS – RISK FACTORS, PRESENTATION AND OUTCOMES
Revathy Manickavasagar
122 “A CHANGE OF HEART”: A CASE SERIES ANALYSIS OF END STAGE KIDNEY DISEASE PATIENTS CHANGING FROM CONSERVATIVE TO ACTIVE DIALYSIS TREATMENT.
Katherine Nguyen
123 PNEUMATIC COMPRESSION DEVICES IN THE PREVENTION OF INTRADIALYTIC HYPOTENSION
Huan Dang, Christopher Sia
124 IS DIABETIC MYONECROSIS MORE COMMON THAN WE THOUGHT? A CLUSTER OF CASES IN PATIENTS WITH END STAGE KIDNEY DISEASE IN CENTRAL AUSTRALIA
Priyanka Subramani
125 HIGH-DOSE INTRAVENOUS METHOTREXATE WITH HIGH-FLUX HAEMODIALYSIS IN TREATMENT OF POST-TRANSPLANT, CENTRAL NERVOUS SYSTEM LYMPHOMA WITH END-STAGE KIDNEY DISEASE
Erin Vaughan
126 AN UNUSUAL CASE OF HYPERCALCAEMIA IN A HAEMODIALYSIS PATIENT
Catherine Wilkinson
127 CONTACT PRECAUTIONS FOR COLONISATION WITH MULTI-DRUG REISTANT ORGANISMS AND HAEMODIALYSIS PATIENT QUALITY OF LIFE AND MOOD: A PILOT CASE CONTROL STUDY
Catherine Wilkinson
128 GASTROINTESTINAL SYMPTOMS IN PATIENTS RECEIVING DIALYSIS: A SYSTEMATIC REVIEW
Jordan Zuvela
47DARWIN, NT | 4 – 6 SEPTEMBER 2017
PO
STE
RS
HAEMODIALYSIS – VASCULAR ACCESS
129 CLINICAL OUTCOMES OF PERCUTANEOUS THROMBECTOMY OF DIALYSIS ACCESS THROMBOSIS BY NEPHROLOGISTS IN CENTRAL AUSTRALIA
David Kiran Fernandes
130 REPORTING FEASIBILITY OF THE USE OF A REAL-TIME DATA REPORTING TOOL TO IMPROVE OUTCOMES OF HAEMODIALYSIS CATHETER COMPLICATIONS ACROSS AUSTRALIA (REDUCCTION)
Sradha Kotwal
131 REVIEW OF ANTI-MICROBIAL RESISTANT ORGANISMS CAUSING VASCULAR ACCESS ASSOCIATED BACTERAEMIA IN HAEMODIALYSIS PATIENTS IN 2015-2016
Laila Parvaresh
132 USE OF A CLINICAL SCORING TOOL IN PREDICTING ARTERIOVENOUS FISTULAS LIKELY TO FAIL TO MATURE
Tahira Scott
133 ROLE OF SERUM GENTAMICIN LEVEL TESTING IN HAEMODIALYSIS PATIENTS RECEIVING GENTAMICIN LOCKS FOR TUNNELED VENOUS CATHETERS
Jacqueline Soraru
134 OMEGA-3 PUFA SUPPLEMENTATION TO PREVENT ARTERIOVENOUS FISTULA AND GRAFT FAILURE: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
Andrea Viecelli
135 VASCULAR ACCESS IN PATIENTS COMMENCING HAEMODIALYSIS – RESULTS OF IMPLEMENTATION OF A QUALITY IMPROVEMENT PROJECT
Tamara Young
PAEDIATRICS
136 THE MULTIDISCIPLINARY PAEDIATRIC RENAL GENETICS CLINIC: A MODEL FOR MAINSTREAMING GENETICS IN MEDICINE
Andrew Mallett
PERITONEAL DIALYSIS
137 CULTURE-INDEPENDENT IDENTIFICATION OF BACTERIA CAUSING PERITONEAL DIALYSIS ASSOCIATED PERITONITIS
Aron Chakera
138 DEVELOPING AN ASSISTED AUTOMATED PERITONEAL DIALYSIS PROGRAM IN WESTERN AUSTRALIA
Aron Chakera
139 RAPID ASSESSMENT OF BACTERIAL LOAD AND RESISTANCE PHENOTYPE IN PERITONEAL DIALYSIS EFFLUENT BY FLOW CYTOMETRY
Aron Chakera
140 AN UNUSUAL CASE OF CATHETER MIGRATION IN A PERITONEAL DIALYSIS PATIENT
Shyamalee Crocker
48 ANZSN | ANNUAL SCIENTIFIC MEETING
141 USE OF DEFERASIROX (EXJADE) FOR IRON OVERLOAD IN PERITONEAL DIALYSIS PATIENTS.
Erwin Yii
142 CLOUDY BAG: NOT ALWAYS PERITONITIS Vinod Khelgi
143 MORGANELLA MORGANII PD-RELATED PERITONITIS IN A LUNG TRANSPLANT PATIENT
Alice Lee
144 PERITONEAL DIALYSIS CATHETERS FOR RECURRENT/REFRACTORY ASCITES DRAINAGE
Eddie Tan
145 RETAINED PERITONEAL DIALYSIS CATHETER TUNNELING DEVICE SEGMENT ASSOCIATED WITH RECURRENT PERITONITIS: A CASE REPORT
Beata Zahorowska
146 GASTROINTESTINAL MUCORMYCOSIS IN A PERITONEAL DIALYSIS PATIENT WITH END STAGE RENAL FAILURE SECONDARY TO AA AMYLOIDOSIS: A CASE REPORT
Beata Zahorowska
TRANSPLANTATION
147 DETECTION OF HEPATITIS C ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS FROM A DECEASED DONOR PREVIOUSLY TREATED FOR HEPATITIS C
Neeru Agarwal
148 A RETROSPECTIVE STUDY OF DONOR NEPHRECTOMY ON RENAL FUNCTION AND APPLICATION OF LIVING KIDNEY DONOR PROFILE INDEX (LKDPI)
Nyi Aung
149 FLUDROCORTISONE IN THE MANAGEMENT OF TUBULOPATHIES POST-RENAL TRANSPLANTATION
Shyamalee Crocker
150 THROMBOLYSIS FOR PULMONARY EMBOLISM EARLY POST-RENAL TRANSPLANTATION
Shyamalee Crocker
151 COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY USE IN END STAGE RENAL FAILURE
Sarah Gleeson
152 THE SYMPTOM BURDEN OF TRANSPLANT PATIENTS COMPARED TO DIALYSIS PATIENTS
Jeffrey Ha
153 EXPECTATIONS AND EXPERIENCES OF FOLLOW UP AND SELF-CARE AFTER LIVING KIDNEY DONATION: A FOCUS GROUP STUDY
Camilla Hanson
154 EARLY GRAFT LOSS DUE TO RECURRENCE OF DIABETIC NEPHROPATHY FOLLOWING LIVE DONOR KIDNEY TRANSPLANTATION
Jack Heron
155 BACILLARY ANGIOMATOSIS IN A RENAL TRANSPLANT RECIPIENT
Vinod Khelgi
49DARWIN, NT | 4 – 6 SEPTEMBER 2017
PO
STE
RS
156 NON-ABO RED BLOOD CELL GROUP ANTIGENS IN RENAL TRANSPLANTATION
Prasanti Kotagiri
157 THE ADOPT TRIAL: A PHARMACOMETRIC STUDY OF THE BETWEEN-OCCASION VARIABILITY IN FREE MYCOPHENOLIC ACID PHARMACOKINETICS PRIOR TO AND IN THE EARLY PHASE POST KIDNEY TRANSPLANT IN SIXTY PROSPECTIVELY RECRUITED ADULTS AND CHILDREN
David Metz
158 RHABDOMYOLYSIS SECONDARY TO SEASONAL INFLUENZA VACCINE IN A RENAL TRANSPLANT RECIPIENT
Amanda Siriwardana
159 SCEDOSPORIUM APIOSPERMUM BONE INFECTION IN A RENAL TRANSPLANT RECIPIENT
Amanda Siriwardana
160 RESISTANT CYTOMEGALOVIRUS DISEASE IN KIDNEY-PANCREAS TRANSPLANT: TREATMENT WITH PRIMED T-CELL THERAPY
Sarah So
161 SPONTANEOUS ATRAUMATIC SPLENIC RUPTURE FOLLOWING INTRAVENOUS IMMUNOGLOBULIN FOR PARVOVIRUS B19 ASSOCIATED PURE RED CELL APLASIA IN A RENAL TRANSPLANT PATIENT – A CASE REPORT
Mark Tiong
162 POST RENAL TRANSPLANT EXTRAPULMONARY TUBERCULOSIS IN AN OVERSEAS-BORN AUSTRALIAN
Catherine Wilkinson
163 TEMPORAL TRENDS IN CLINICAL OUTCOMES OF KIDNEY TRANSPLANTATION FROM 1996 TO 2013 IN AUSTRALIA AND NEW ZEALAND
Wing Chi Gigi Yeung
164 CORRELATION AND AGREEMENT BETWEEN THE NUMBER OF CLASS I AND II EPLET MISMATCHES CALCULATED USING SEROLOGICAL, LOW-INTERMEDIATE AND HIGH RESOLUTION MOLECULAR HUMAN LEUKOCYTE ANTIGEN TYPING METHODS
Wai Lim
165 MORTALITY FOLLOWING PRIMARY RENAL ALLOGRAFT FAILURE – A REGISTRY ANALYSIS
Wai Lim
WIRELESSNETWORK NAME: ANZSN ASM
PASSWORD: anzsnasm
50 ANZSN | ANNUAL SCIENTIFIC MEETING
LOADING DOCK
ANZSN 2017POSTERS FLOORPLAN
ENTRY/EXIT
FOYER
08
BARISTA CAFE
17
REGISTRATION
18
19
16
15
070605
#01#02 #03 #04 #05 #06 #07
#20 #19 #18
#37 #36 #35 #34
#46 #45 #44 #43 #42
#28 #27 #26 #25 #24
#21 #22 #23
#29 #30 #31#32 #33
#38 #39 #40#41
#47 #48 #49#50 #51
#72 #73 #74#75 #76 #77
#78 #79 #80#81 #82 #83
#89 #88 #87#86 #85 #84
#95 #94#93 #92 #91 #90
#132 #131 #130 #129 #128 #127 #126 #125#124 #123 #122 #121
#137 #138 #139 #140 #141 #142
#154 #155 #156 #157 #158 #159
#160 #161 #162 #163 #164 #165
#151 #152 #153
#148 #147 #146 #145 #144 #143
#08#09 #10 #11 #12 #13 #14#15 #16 #17
#52#53#54#55#56 #57#58#59#60#61#62#63#64#65#66#67#68 #69 #70 #71
04 09
10
11
121314
03
02
01
#96#97 #98 #99 #100
#133#134 #135 #136
#149#150
#107#106#105 #104 #103 #102
#108#109#110 #111 #112 #113
#114#115#116 #117 #118 #119 #120
#101
EXHIBITORS & POSTERS FLOORPLAN
51DARWIN, NT | 4 – 6 SEPTEMBER 2017
# ORGANISATION
01 Vifor Pharma
02 Nxstage Medical
03 ANZSIN
04 AstraZeneca
05 Australasian Kidney Trials Network & ANZDATA
06 KHA – CARI & Cochrane Kidney Transplant
07 Kidney Health Australia
08 Western Desert Nganampa Walytja Palyantjaku Tjutaku
09 Ortho Clinical Diagnostics
10 MSD
11 Alexion Pharmaceuticals Australasia
12 Paperbark Woman
13 Novartis
14 Sanofi Australia
15 BAXTER
16 Fresenius
17 Otsuka Australia Pharmaceutical
18 Roche Products
19 AMGEN
EXHIBITORS
# Numbers indicate posters. See poster list on page 38 – 49.
52 ANZSN | ANNUAL SCIENTIFIC MEETING
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
NOTES
53DARWIN, NT | 4 – 6 SEPTEMBER 2017
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
NOTES
54 ANZSN | ANNUAL SCIENTIFIC MEETING
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
NOTES
DARWIN MAP
1. DOWNLOADGo to the apple store or the Android play store and search for “Conference Design”. Download the Conference Design App onto your device.
3. FIND ANZSN 2017Select the ANZSN 2017 guide from the list; this download may take a few minutes.
2. OPEN THE APP
Find and open the Conference Design App on your device. Click on download guides at the bottom of your screen.
4. EXPLORE!Open the guide and click on the menu items to browse ASM information. You can register a delegate profile to connect with others.
ANZSN 2017
www.anzsnasm.com
ANZSN ASM ASTELLAS APPWe encourage you to download our mobile guide to enhance your experience at the ANZSN ASM 2017. You’ll be able to plan your day with a personalised schedule, take notes, connect with other delegates and browse sponsors, maps and general conference information.
The app is compatible with iPhones, iPads, iPod Touches and Android devices.